Antipsychotic Medication and Risk of Incident Seizure in People with Autism Spectrum Disorder: Analyses with Cohort and Within Individual Study Designs / Basmah H. ALFAGEH in Journal of Autism and Developmental Disorders, 52-11 (November 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-11 (November 2022) . - p.4817-4827 Titre : Antipsychotic Medication and Risk of Incident Seizure in People with Autism Spectrum Disorder: Analyses with Cohort and Within Individual Study Designs Type de document : Texte imprimé et/ou numérique Auteurs : Basmah H. ALFAGEH, Auteur ; Frank M. C. BESAG, Auteur ; Le GAO, Auteur ; Tian-Tian MA, Auteur ; Kenneth K. C. MAN, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur Article en page(s) : p.4817-4827 Langues : Anglais (eng) Mots-clés : Antipsychotic Agents/adverse effects  Autism Spectrum Disorder/drug therapy/epidemiology  Cohort Studies  Humans  Psychotropic Drugs/therapeutic use  Retrospective Studies  Seizures/chemically induced/drug therapy/epidemiology  Antipsychotic medication  Autism spectrum disorder (ASD)  Incident seizure  Psychotropic medication Index. décimale : PER Périodiques Résumé : There are many case reports of seizures apparently associated with the prescription of antipsychotics. This study aimed to examine whether there is an association between the prescription of antipsychotics and incident seizures in individuals with autism spectrum disorder using retrospective data based on patients' chart review. A cohort study was conducted to compare the rate of incident seizure between 3923 users of antipsychotics with 10,086 users of other psychotropics. This was followed by a self-controlled case series (SCCS) analysis of 149 patients to eliminate the effect of time-invariant confounders. The results showed no evidence of increased risk of seizure after exposure to antipsychotic agents (Hazard Ratio 1.28, 95% CI 0.74-2.19) compared to other psychotropics. En ligne : http://dx.doi.org/10.1007/s10803-021-05208-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489 [article] Antipsychotic Medication and Risk of Incident Seizure in People with Autism Spectrum Disorder: Analyses with Cohort and Within Individual Study Designs [Texte imprimé et/ou numérique] / Basmah H. ALFAGEH, Auteur ; Frank M. C. BESAG, Auteur ; Le GAO, Auteur ; Tian-Tian MA, Auteur ; Kenneth K. C. MAN, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur . - p.4817-4827. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-11 (November 2022) . - p.4817-4827 Mots-clés : Antipsychotic Agents/adverse effects  Autism Spectrum Disorder/drug therapy/epidemiology  Cohort Studies  Humans  Psychotropic Drugs/therapeutic use  Retrospective Studies  Seizures/chemically induced/drug therapy/epidemiology  Antipsychotic medication  Autism spectrum disorder (ASD)  Incident seizure  Psychotropic medication Index. décimale : PER Périodiques Résumé : There are many case reports of seizures apparently associated with the prescription of antipsychotics. This study aimed to examine whether there is an association between the prescription of antipsychotics and incident seizures in individuals with autism spectrum disorder using retrospective data based on patients' chart review. A cohort study was conducted to compare the rate of incident seizure between 3923 users of antipsychotics with 10,086 users of other psychotropics. This was followed by a self-controlled case series (SCCS) analysis of 149 patients to eliminate the effect of time-invariant confounders. The results showed no evidence of increased risk of seizure after exposure to antipsychotic agents (Hazard Ratio 1.28, 95% CI 0.74-2.19) compared to other psychotropics. En ligne : http://dx.doi.org/10.1007/s10803-021-05208-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489

Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder / David DALEY in Journal of Child Psychology and Psychiatry, 59-9 (September 2018)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 59-9 (September 2018) . - p.932-947 Titre : Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder Type de document : Texte imprimé et/ou numérique Auteurs : David DALEY, Auteur ; Saskia VAN DER OORD, Auteur ; Maite FERRIN, Auteur ; Samuele CORTESE, Auteur ; Marina DANCKAERTS, Auteur ; Manfred DOEPFNER, Auteur ; Barbara J. VAN DEN HOOFDAKKER, Auteur ; David COGHILL, Auteur ; Margaret THOMPSON, Auteur ; Philip ASHERSON, Auteur ; Tobias BANASCHEWSKI, Auteur ; Daniel BRANDEIS, Auteur ; Jan K. BUITELAAR, Auteur ; Ralf W. DITTMANN, Auteur ; Chris HOLLIS, Auteur ; Martin HOLTMANN, Auteur ; Eric KONOFAL, Auteur ; Michel LECENDREUX, Auteur ; Aribert ROTHENBERGER, Auteur ; Paramala SANTOSH, Auteur ; Emily SIMONOFF, Auteur ; Cesar SOUTULLO, Auteur ; Hans Christoph STEINHAUSEN, Auteur ; Argyris STRINGARIS, Auteur ; Eric TAYLOR, Auteur ; Ian C. K. WONG, Auteur ; Alessandro ZUDDAS, Auteur ; Edmund J. S. SONUGA-BARKE, Auteur Article en page(s) : p.932-947 Langues : Anglais (eng) Mots-clés : ADHD  behaviour therapy  conduct disorder  parent training  treatment trials Index. décimale : PER Périodiques Résumé : Background Behavioural interventions are recommended for use with children and young people with attention deficit hyperactivity disorder (ADHD); however, specific guidance for their implementation based on the best available evidence is currently lacking. Methods This review used an explicit question and answer format to address issues of clinical concern, based on expert interpretation of the evidence with precedence given to meta-analyses of randomised controlled trials. Results On the basis of current evidence that takes into account whether outcomes are blinded, behavioural intervention cannot be supported as a front-line treatment for core ADHD symptoms. There is, however, evidence from measures that are probably blinded that these interventions benefit parenting practices and improve conduct problems which commonly co-occur with ADHD, and are often the main reason for referral. Initial positive results have also been found in relation to parental knowledge, children's emotional, social and academic functioning ? although most studies have not used blinded outcomes. Generic and specialised ADHD parent training approaches ? delivered either individually or in groups ? have reported beneficial effects. High-quality training, supervision of therapists and practice with the child, may improve outcomes but further evidence is required. Evidence for who benefits the most from behavioural interventions is scant. There is no evidence to limit behavioural treatments to parents with parenting difficulties or children with conduct problems. There are positive effects of additive school-based intervention for the inattentive subtype. Targeting parental depression may enhance the effects of behavioural interventions. Conclusions Parent training is an important part of the multimodal treatment of children with ADHD, which improves parenting, reduces levels of oppositional and noncompliant behaviours and may improve other aspects of functioning. However, blinded evidence does not support it as a specific treatment for core ADHD symptoms. More research is required to understand how to optimise treatment effectiveness either in general or for individual patients and explore potential barriers to treatment uptake and engagement. In terms of selecting which intervention formats to use, it seems important to acknowledge and respond to parental treatment preferences. En ligne : https://doi.org/10.1111/jcpp.12825 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=368 [article] Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder [Texte imprimé et/ou numérique] / David DALEY, Auteur ; Saskia VAN DER OORD, Auteur ; Maite FERRIN, Auteur ; Samuele CORTESE, Auteur ; Marina DANCKAERTS, Auteur ; Manfred DOEPFNER, Auteur ; Barbara J. VAN DEN HOOFDAKKER, Auteur ; David COGHILL, Auteur ; Margaret THOMPSON, Auteur ; Philip ASHERSON, Auteur ; Tobias BANASCHEWSKI, Auteur ; Daniel BRANDEIS, Auteur ; Jan K. BUITELAAR, Auteur ; Ralf W. DITTMANN, Auteur ; Chris HOLLIS, Auteur ; Martin HOLTMANN, Auteur ; Eric KONOFAL, Auteur ; Michel LECENDREUX, Auteur ; Aribert ROTHENBERGER, Auteur ; Paramala SANTOSH, Auteur ; Emily SIMONOFF, Auteur ; Cesar SOUTULLO, Auteur ; Hans Christoph STEINHAUSEN, Auteur ; Argyris STRINGARIS, Auteur ; Eric TAYLOR, Auteur ; Ian C. K. WONG, Auteur ; Alessandro ZUDDAS, Auteur ; Edmund J. S. SONUGA-BARKE, Auteur . - p.932-947. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 59-9 (September 2018) . - p.932-947 Mots-clés : ADHD  behaviour therapy  conduct disorder  parent training  treatment trials Index. décimale : PER Périodiques Résumé : Background Behavioural interventions are recommended for use with children and young people with attention deficit hyperactivity disorder (ADHD); however, specific guidance for their implementation based on the best available evidence is currently lacking. Methods This review used an explicit question and answer format to address issues of clinical concern, based on expert interpretation of the evidence with precedence given to meta-analyses of randomised controlled trials. Results On the basis of current evidence that takes into account whether outcomes are blinded, behavioural intervention cannot be supported as a front-line treatment for core ADHD symptoms. There is, however, evidence from measures that are probably blinded that these interventions benefit parenting practices and improve conduct problems which commonly co-occur with ADHD, and are often the main reason for referral. Initial positive results have also been found in relation to parental knowledge, children's emotional, social and academic functioning ? although most studies have not used blinded outcomes. Generic and specialised ADHD parent training approaches ? delivered either individually or in groups ? have reported beneficial effects. High-quality training, supervision of therapists and practice with the child, may improve outcomes but further evidence is required. Evidence for who benefits the most from behavioural interventions is scant. There is no evidence to limit behavioural treatments to parents with parenting difficulties or children with conduct problems. There are positive effects of additive school-based intervention for the inattentive subtype. Targeting parental depression may enhance the effects of behavioural interventions. Conclusions Parent training is an important part of the multimodal treatment of children with ADHD, which improves parenting, reduces levels of oppositional and noncompliant behaviours and may improve other aspects of functioning. However, blinded evidence does not support it as a specific treatment for core ADHD symptoms. More research is required to understand how to optimise treatment effectiveness either in general or for individual patients and explore potential barriers to treatment uptake and engagement. In terms of selecting which intervention formats to use, it seems important to acknowledge and respond to parental treatment preferences. En ligne : https://doi.org/10.1111/jcpp.12825 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=368

Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK / Basmah H. ALFAGEH in Journal of Autism and Developmental Disorders, 50-2 (February 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.625-633 Titre : Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK Type de document : Texte imprimé et/ou numérique Auteurs : Basmah H. ALFAGEH, Auteur ; Kenneth K. C. MAN, Auteur ; Frank M. C. BESAG, Auteur ; Tariq M. ALHAWASSI, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur Article en page(s) : p.625-633 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Incidence  Prevalence  Psychotropic medication Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. En ligne : http://dx.doi.org/10.1007/s10803-019-04291-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 [article] Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK [Texte imprimé et/ou numérique] / Basmah H. ALFAGEH, Auteur ; Kenneth K. C. MAN, Auteur ; Frank M. C. BESAG, Auteur ; Tariq M. ALHAWASSI, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur . - p.625-633. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.625-633 Mots-clés : Autism spectrum disorder  Incidence  Prevalence  Psychotropic medication Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. En ligne : http://dx.doi.org/10.1007/s10803-019-04291-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416

Research Review: The role of diet in the treatment of attention-deficit/hyperactivity disorder – an appraisal of the evidence on efficacy and recommendations on the design of future studies / Jim STEVENSON in Journal of Child Psychology and Psychiatry, 55-5 (May 2014)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 55-5 (May 2014) . - p.416-427 Titre : Research Review: The role of diet in the treatment of attention-deficit/hyperactivity disorder – an appraisal of the evidence on efficacy and recommendations on the design of future studies Type de document : Texte imprimé et/ou numérique Auteurs : Jim STEVENSON, Auteur ; Jan K. BUITELAAR, Auteur ; Samuele CORTESE, Auteur ; Maite FERRIN, Auteur ; Eric KONOFAL, Auteur ; Michel LECENDREUX, Auteur ; Emily SIMONOFF, Auteur ; Ian C. K. WONG, Auteur ; Edmund J. S. SONUGA-BARKE, Auteur ; Adhd Guidelines Group THE EUROPEAN, Auteur Article en page(s) : p.416-427 Mots-clés : ADHD  meta-analysis  food colours  fatty acid  elimination diet  food supplements Index. décimale : PER Périodiques Résumé : Background The efficacy of three dietary treatments for ADHD has been repeatedly tested in randomized controlled trials (RCTs). These interventions are restricted elimination diets (RED), artificial food colour elimination (AFCE) and supplementation with free fatty acids (SFFA). There have been three systematic reviews and associated meta-analyses of the RCTs for each of these treatments. Scope The aim of this review is to critically appraise the studies on the dietary treatments of ADHD, to compare the various meta-analyses of their efficacy that have been published and to identify where the design of such RCTs could be improved and where further investigations are needed. Findings The meta-analyses differ in the inclusion and exclusion criteria applied to potentially eligible studies. The range of average effect sizes in standard deviation units is RED (0.29–1.2), AFCE (0.18–0.42) and SFFA (0.17–0.31). The methodology of many of the trials on which the meta-analyses are based is weak. Conclusions Nevertheless, there is evidence from well-conducted studies for a small effect of SFFA. Restricted elimination diets may be beneficial, but large-scale studies are needed on unselected children, using blind assessment and including assessment of long-term outcome. Artificial food colour elimination is a potentially valuable treatment but its effect size remains uncertain, as does the type of child for whom it is likely to be efficacious. There are additional dietary supplements that have been used with children with ADHD. A systematic search identified 11 RCTs that investigated the effects of these food supplements. Despite positive results for some individual trials, more studies are required before conclusions can be reached on the value in reducing ADHD symptoms of any of these additional supplements. En ligne : http://dx.doi.org/10.1111/jcpp.12215 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=231 [article] Research Review: The role of diet in the treatment of attention-deficit/hyperactivity disorder – an appraisal of the evidence on efficacy and recommendations on the design of future studies [Texte imprimé et/ou numérique] / Jim STEVENSON, Auteur ; Jan K. BUITELAAR, Auteur ; Samuele CORTESE, Auteur ; Maite FERRIN, Auteur ; Eric KONOFAL, Auteur ; Michel LECENDREUX, Auteur ; Emily SIMONOFF, Auteur ; Ian C. K. WONG, Auteur ; Edmund J. S. SONUGA-BARKE, Auteur ; Adhd Guidelines Group THE EUROPEAN, Auteur . - p.416-427. in Journal of Child Psychology and Psychiatry > 55-5 (May 2014) . - p.416-427 Mots-clés : ADHD  meta-analysis  food colours  fatty acid  elimination diet  food supplements Index. décimale : PER Périodiques Résumé : Background The efficacy of three dietary treatments for ADHD has been repeatedly tested in randomized controlled trials (RCTs). These interventions are restricted elimination diets (RED), artificial food colour elimination (AFCE) and supplementation with free fatty acids (SFFA). There have been three systematic reviews and associated meta-analyses of the RCTs for each of these treatments. Scope The aim of this review is to critically appraise the studies on the dietary treatments of ADHD, to compare the various meta-analyses of their efficacy that have been published and to identify where the design of such RCTs could be improved and where further investigations are needed. Findings The meta-analyses differ in the inclusion and exclusion criteria applied to potentially eligible studies. The range of average effect sizes in standard deviation units is RED (0.29–1.2), AFCE (0.18–0.42) and SFFA (0.17–0.31). The methodology of many of the trials on which the meta-analyses are based is weak. Conclusions Nevertheless, there is evidence from well-conducted studies for a small effect of SFFA. Restricted elimination diets may be beneficial, but large-scale studies are needed on unselected children, using blind assessment and including assessment of long-term outcome. Artificial food colour elimination is a potentially valuable treatment but its effect size remains uncertain, as does the type of child for whom it is likely to be efficacious. There are additional dietary supplements that have been used with children with ADHD. A systematic search identified 11 RCTs that investigated the effects of these food supplements. Despite positive results for some individual trials, more studies are required before conclusions can be reached on the value in reducing ADHD symptoms of any of these additional supplements. En ligne : http://dx.doi.org/10.1111/jcpp.12215 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=231

The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries / Angel Y. S. WONG in Autism Research, 7-5 (October 2014)  

Public ISBD [article]  inAutism Research > 7-5 (October 2014) . - p.543-554 Titre : The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries Type de document : Texte imprimé et/ou numérique Auteurs : Angel Y. S. WONG, Auteur ; Yingfen HSIA, Auteur ; Esther W. CHAN, Auteur ; Declan G. M. MURPHY, Auteur ; Emily SIMONOFF, Auteur ; Jan K. BUITELAAR, Auteur ; Ian C. K. WONG, Auteur Article en page(s) : p.543-554 Langues : Anglais (eng) Mots-clés : epidemiology  Gross Domestic Product  Psychopharmacology  Multinational study Index. décimale : PER Périodiques Résumé : There is significant variation in prescriptions among countries in clinical practice for the treatment of comorbidities associated with autism spectrum disorder (ASD). It has been suggested that many people with mental health disorders in low-/middle-income countries do not receive adequate treatment. Hence, this study investigated psychopharmacological treatment patterns for ASD comorbidities in 30 countries and the association between country's income and prescription rates. The IMS Prescribing Insights database was used to investigate prescription patterns for ASD comorbidity treatment from 2007 to 2012. Data were obtained from 30 countries in continents of Europe, Asia, Oceania, Central America, South America, and Africa. The gross domestic product (GDP) per capita was used as a proxy for each country's income. Spearman correlation was used to examine the association between prescription rate and GDP per capita. The highest prescription rates were found in Western Europe (3.89–36.36/10,000) while the lowest prescription rates were found in Asian countries, such as Turkey, Indonesia, Saudi Arabia, and Pakistan (0.04–0.82/10,000). The most commonly prescribed drug for ASD comorbidity treatment in most of the countries was risperidone, but antidepressants and antiepileptic drugs were also frequently prescribed. There was a significant positive correlation between GDP per capita and prescription rate (Spearman ??=?0.60; P?=?0.0011; 95% confidence interval 0.27–0.81), that is, the higher the GDP per capita, the higher the prescription rate. There are marked international differences in prescription rates, and this is partially accounted by economic factors. Future research should combine more data for ASD comorbidity treatment to explore the disparity of psychopharmacological treatment between countries. Autism Res 2014, 7: 543–554. © 2014 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1391 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=241 [article] The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries [Texte imprimé et/ou numérique] / Angel Y. S. WONG, Auteur ; Yingfen HSIA, Auteur ; Esther W. CHAN, Auteur ; Declan G. M. MURPHY, Auteur ; Emily SIMONOFF, Auteur ; Jan K. BUITELAAR, Auteur ; Ian C. K. WONG, Auteur . - p.543-554. Langues : Anglais (eng) in Autism Research > 7-5 (October 2014) . - p.543-554 Mots-clés : epidemiology  Gross Domestic Product  Psychopharmacology  Multinational study Index. décimale : PER Périodiques Résumé : There is significant variation in prescriptions among countries in clinical practice for the treatment of comorbidities associated with autism spectrum disorder (ASD). It has been suggested that many people with mental health disorders in low-/middle-income countries do not receive adequate treatment. Hence, this study investigated psychopharmacological treatment patterns for ASD comorbidities in 30 countries and the association between country's income and prescription rates. The IMS Prescribing Insights database was used to investigate prescription patterns for ASD comorbidity treatment from 2007 to 2012. Data were obtained from 30 countries in continents of Europe, Asia, Oceania, Central America, South America, and Africa. The gross domestic product (GDP) per capita was used as a proxy for each country's income. Spearman correlation was used to examine the association between prescription rate and GDP per capita. The highest prescription rates were found in Western Europe (3.89–36.36/10,000) while the lowest prescription rates were found in Asian countries, such as Turkey, Indonesia, Saudi Arabia, and Pakistan (0.04–0.82/10,000). The most commonly prescribed drug for ASD comorbidity treatment in most of the countries was risperidone, but antidepressants and antiepileptic drugs were also frequently prescribed. There was a significant positive correlation between GDP per capita and prescription rate (Spearman ??=?0.60; P?=?0.0011; 95% confidence interval 0.27–0.81), that is, the higher the GDP per capita, the higher the prescription rate. There are marked international differences in prescription rates, and this is partially accounted by economic factors. Future research should combine more data for ASD comorbidity treatment to explore the disparity of psychopharmacological treatment between countries. Autism Res 2014, 7: 543–554. © 2014 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1391 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=241

---

1 (1 - 5 / 5)